Clinical trials: Diarrhea Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
A study to verify the superiority of ramosetron hydrochloride (Irribow Tablets) to placebo for male patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01225237
- Testing
- Ramosetron
- Where
- 4 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhea
Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome
Randomized controlled clinical study has been proposed to evaluate the safety and efficacy of ES1 probiotic strain and heat-treated ES1 postbiotic strain in individuals suffering from IBS-D.
- Trial name
- NCT05339243
- Testing
- ES 1, HT ES1
- Where
- 8 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Irritable Bowel Syndrome, Colonic Diseases
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).
- Conditions
- Irritable Bowel Syndrome, Colonic Diseases, Diarrhea, Gastrointestinal Disease
- Trial name
- NCT00101725
- Testing
- crofelemer
- Where
- 29 sites in United States
- Volunteers
- 245 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea
Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
To compare with a randomized trial (n=15 per treatment group), effects of colesevelam and placebo treatment, on colonic transit, bowel functions, permeability and tight junction expression in rectosigmoid mucosa of IBS-D with…
- Conditions
- Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption
- Trial name
- NCT03270085
- Testing
- Colesevelam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Diarrhoea Predominant Irritable Bowel Syndrome, IBS
Analyzing IBS to Identify Biomarkers and Microbiome Signatures
Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to…
- Trial name
- NCT02419963
- Testing
- endoscopy for tissue biopsy, Blood Sample, Stool Sample
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Diarrhea Predominant Irritable Bowel Syndrome
The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome
The investigators will evaluate the efficacy of soy dietary fiber in adults with diarrhea predominant irritable bowel syndrome.
- Trial name
- NCT01373034
- Testing
- Soy Dietary Fiber, Rice powder
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Seoul National University Hospital
Irritable Colon
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
This study will look at colonic mucosal blood flow in subjects who have taken alosetron vs placebo and healthy volunteers vs diarrhea-predominant Irritable Bowel Syndrome (d-IBS) patients.
- Trial name
- NCT00370032
- Testing
- alosetron
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional…
- Trial name
- NCT00067561
- Testing
- Alosetron
- Where
- 178 sites in United States, Australia
- Volunteers
- 702 people
- Sponsor
- GlaxoSmithKline
Irritable Colon, Irritable Bowel Syndrome (IBS)
Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
The purpose of this study is to compare the safety and effectiveness of as needed versus fixed dosing of an investigational medication for women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed…
- Trial name
- NCT00067457
- Testing
- alosetron
- Where
- 191 sites in United States, Australia
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome (IBS)
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- RESTORE (NCT01844180)
- Testing
- ONO-2952
- Where
- 48 sites in United States
- Volunteers
- 200 people
- Sponsor
- Ono Pharma USA Inc
Diarrhea-predominant Irritable Bowel Syndrome
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the efficacy and safety of YM060 once daily for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) for a long-term period (up to 52 weeks).
- Trial name
- NCT01736423
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 151 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome, Diarrhea
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
Irritable bowel syndrome is a highly prevalent disorder and consumes many health resources. Its physiopathogenesis is multifactorial.
- Trial name
- NCT05207618
- Testing
- ARBOX (QUEBRACHO AND CHESNUT EXTRACT)
- Where
- Argentina
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas José de San Martín
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Diarrhoea Predominant Irritable Bowel Syndrome
Retrospective Study of IBS-D Patients Previously Receiving SBI
This is a retrospective study designed to gather outcomes data from existing medical charts from patients who have taken EnteraGam for management of their IBS-D for at least eight weeks.
- Trial name
- NCT02661425
- Testing
- EnteraGam
- Where
- 16 sites in United States
- Volunteers
- 165 people
- Sponsor
- Entera Health, Inc
Irritable Bowel Syndrome
Moxibustion for Diarrhea-predominant Irritable Bowel Syndrome
To observe the safety and efficacy of moxibustion on diarrhea-predominant irritable bowel syndrome and evaluation by Magnetic Resonance Imaging (MRI), Event related potential (ERP).
- Trial name
- NCT02421627
- Testing
- moxibustion
- Where
- 3 sites in China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Irritable Bowel Syndrome, Diarrhea
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?
Our hypothesis is that the medication approved for treatment of high blood cholesterol levels, Colesevelam HCl (WELCHOL), decreases colonic transit and permeability in patients with diarrhea due to irritable bowel syndrome.
- Trial name
- welchol (NCT00911612)
- Testing
- Colesevelam
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
IBS - Irritable Bowel Syndrome
Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients
This is a Phase IV, open-label, single-center, proof-of-concept, pilot study to evaluate the effect of Lactibiane Tolerance® in treating leaky gut in IBS-D patients.
- Trial name
- NCT04898257
- Testing
- Multistrain probiotic
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Larena SAS
Diarrhea Predominant Irritable Bowel Syndrome
Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)
The purposes of this study are to prospectively determine the effect of a very low carbohydrate diet on quality of life and gastrointestinal symptoms in patients with diarrhea-predominant irritable bowel syndrome (IBS-D); and to…
- Trial name
- NCT00616200
- Testing
- Very low carbohydrate diet
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
IBS (Irritable Bowel Syndrome)
Transcranial Magnetic Stimulation and Pharmacologic/Probiotic Interventions for Diarrhea-Predominant IBS
What is the study about? This study is for adults with diarrhea-predominant irritable bowel syndrome (IBS-D) who suffer from chronic visceral pain.
- Trial name
- rTMS (NCT07172139)
- Testing
- Active rTMS + Pinaverium Bromide, Active rTMS + Bifidobacterium
- Volunteers
- 140 people
- Sponsor
- Rui Li
Diarrhea Predominant Irritable Bowel Syndrome
Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance
The main objective of the study is to evaluate the effect on intestinal permeability of a supplementation with Lactibiane Tolérance® for 4 weeks (28 days) in patients suffering from irritable bowel syndrome (IBS) with diarrhea…
- Trial name
- PILATE (NCT02728063)
- Testing
- Lactibiane Tolerance
- Where
- France
- Volunteers
- 30 people
- Sponsor
- PiLeJe